… news release. In February 2024, the FDA granted priority review for this indication. Continued approval for the indication may be dependent on …
FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma
Share This Story, Choose Your Platform!
About the Author:
Leave A Comment